Last updated: July 27, 2026
Iopamidol injection 300 mg I/mL (Isovue-300) is a contrast agent with largely mature, low-growth market dynamics. As of 2026, the product is long past typical small-molecule new-product exclusivity windows, and the competitive landscape is dominated by multi-source generics and authorized equivalents across iodinated contrast portfolios. Clinical trial activity for iopamidol products is limited compared with newer contrast classes and is mainly driven by comparative safety/compatibility studies, workflow trials, and occasional formulation or delivery-device studies rather than first-in-class efficacy programs.
Isovue-300 (iopamidol) clinical trials update: what studies are active or recently completed?
Current status of iopamidol clinical development
- Iopamidol is an established iodinated contrast medium with broad regulatory approval history.
- Recent years show clinical activity concentrated in:
- Comparative tolerability and safety in specific imaging workflows (CT angiography, enhanced CT, urography).
- Renal safety and hydration protocols in patients at risk for contrast-associated acute kidney injury (CA-AKI).
- Injection technique and contrast administration parameters (rate, volume, temperature, biphasic protocols).
- Limited formulation or device-related studies (packaging, compatibility, administration systems).
What this means for “clinical trials update”
- The commercial signal for iopamidol like Isovue-300 is less about new pivotal trials and more about:
- Ongoing post-marketing safety monitoring.
- Local comparative studies that affect formulary adoption.
- Tender-driven contracting and supply reliability rather than breakthrough clinical outcomes.
Clinical endpoints commonly used in recent iopamidol studies
- Incidence of hypersensitivity reactions.
- Vital sign changes during administration.
- Renal function change (serum creatinine, eGFR) at follow-up timepoints.
- Incidence and severity grading of contrast-related adverse events.
- Image quality metrics for CT reconstruction quality and artifact reduction.
Which patient populations do recent iopamidol studies focus on?
- Higher-risk renal populations (diabetic nephropathy, CKD).
- Patients with prior hypersensitivity to contrast media.
- Emergency and inpatient CT utilization cohorts where workflow timing matters.
- Pediatrics and geriatrics in protocol-specific imaging studies.
Does iopamidol have ongoing trials in 2024–2026?
Public trial activity for iopamidol products tends to be sporadic and study-specific. For business planning, the most actionable view is that Isovue-300 competition is driven by:
- Drug supply assurance and contract pricing.
- Formulary preferences established by prior safety data and institutional protocols.
- Equivalent authorization status across iodinated contrast agents.
How big is the Isovue-300 market and what are the key demand drivers?
Market sizing reality for mature contrast agents
- Iopamidol and its branded equivalents operate in a large but commoditized segment of radiology contrast media.
- Growth is typically linked to:
- CT utilization trends.
- Expansion of imaging indications.
- Hospital growth and throughput.
- Clinical guidelines influencing contrast selection and dosing protocols.
Primary demand drivers
- Rising CT scan volumes.
- Growth in angiography, oncology imaging surveillance, and trauma imaging.
- Protocol-driven preference for specific iodinated contrast agents by formulary.
Constraints
- Price erosion from generics and authorized alternatives.
- Supply continuity and packaging/plant reliability.
- Periodic shifts in contracting that re-rank suppliers.
Where does Isovue-300 fit vs other iodinated contrasts?
Isovue-300 competes on:
- Price and contract terms.
- Brand familiarity in order systems.
- Supply and lot-to-lot performance consistency.
- Institutional safety experience with iopamidol specifically.
Isovue-300 exclusivity and patent estate: what patents protect iopamidol injection 300 mg I/mL?
Bottom-line exclusivity position
- For iopamidol injection products, the patent landscape is typically mature.
- For business decisions, exclusivity impact is usually limited to:
- Particular formulation/process claims tied to specific labeled products or packaging.
- Method-of-use claims that are narrower and less likely to block generics in practice for a widely-used contrast medium.
- The practical market access question is usually not “Is there still exclusivity?” but “Which competitors are authorized and available under current FDA approvals and labeling?”
H2: When does Isovue-300 lose exclusivity?
Given the established age of iopamidol as an active ingredient, Isovue-300 is generally treated as outside the core exclusivity window. Market access is driven by:
- Current FDA approval status (brand vs authorized generic vs other approved versions).
- Patent listings that may or may not include relevant Orange Book entries for the exact strength and dosage form.
H3: What patent categories are most relevant to contrast agents?
- Composition of matter (rare for late-stage competitive access since active ingredients are old).
- Manufacturing/process claims.
- Packaging and specific concentration/fractionation-related claims.
- Method-of-use claims (often limited, and sometimes hard to enforce against label carveouts or substitution).
What is the Orange Book status of Isovue-300 (iopamidol 300 mg I/mL)?
Featured snippet answer (operational view)
Isovue-300 is an established product with multi-source competition. Orange Book protection, if any, tends to be limited to specific, late-cycle patent listings rather than blocking broad generic availability for a commodity concentration.
How to interpret Orange Book relevance
- Contrast agent market launches depend on whether an applicant can:
- File with a substantially similar formulation and labeling strategy.
- Avoid patented methods and device/packaging claims that would trigger litigation risk.
- Achieve bioequivalence or other regulatory acceptance for the applicable pathway (for drug-device style considerations, sometimes label or administration method matters).
What generic entry risks exist for Isovue-300?
Risk profile
- For mature iodinated contrast products, generic entry risk is usually lower than for new chemical entities, but:
- Litigation risk can persist around process claims or specific formulation details.
- If Orange Book lists patents tied to manufacturing steps, entrants may face Paragraph IV or carveout strategy constraints.
Main real-world entry blockers
- Supply chain and manufacturing capacity for iodinated contrast.
- Quality system readiness for injectable sterile products.
- Contracting barriers: hospitals and distributors may prioritize already-contracted suppliers.
Isovue-300 Paragraph IV challenges: which companies have targeted iopamidol products?
General market pattern
- In established contrast agent categories, Paragraph IV-style litigation is less visually dominant than for oncology or high-value branded biologics, but patent challenges can occur.
- For business planning, the key is that competitive entry has already occurred broadly across iodinated contrasts. New entrants focus on:
- Strength matching and label alignment.
- Pricing and distribution reach.
- Supply reliability.
Operational consequence
- The competitive set already includes authorized and generic equivalents, making new Paragraph IV events less likely to represent a step-change in market dynamics.
How does Isovue-300 compare with other iopamidol brands and competing iodinated contrast media?
Comparison framework
Isovue-300 (iopamidol 300 mg I/mL) competes with:
- Other iodinated nonionic contrast agents (same therapeutic category, different active ingredients).
- Other iopamidol concentrations and packaging formats.
- Authorized generics and branded generics.
Where substitution is typically easiest
- Same indication and imaging workflow approvals.
- Label similarities for renal precautions, hypersensitivity warnings, and dosing guidance.
- Institutional protocols that allow interchangeability within iodinated contrast classes.
Key differentiators that still matter in contracting
- Total cost per exam after dosing.
- Pallet and packaging logistics.
- Readiness for delivery volumes and emergency supply.
- Distribution relationships.
Market projection for Isovue-300: revenue outlook, pricing pressure, and volume trends
Projection stance for a mature contrast product
- Isovue-300’s revenue trajectory is typically characterized by:
- Flat-to-slight volume growth aligned with CT utilization.
- Continued pricing pressure from multi-source competition.
- Share shifts driven by contracts, tenders, and distributor preferences.
Model components for projection
- Volume: correlation with CT procedure volumes and protocol adoption.
- Price: average selling price decline from generic penetration.
- Mix: changes between strength/concentration variants and packaging sizes.
- Geographic: US dominated by large hospital systems and group purchasing organizations.
Base case projection (directional)
- Revenue: modest growth or stagnation in nominal terms if volume rises enough to offset price erosion.
- Margin: compression due to commodity contracting and competitive tender pricing.
- Share: potential volatility between major sellers based on supply performance and contract cycles.
Upside and downside scenarios
- Upside: improved supply reliability and favorable formulary decisions.
- Downside: further price erosion from additional authorized competitors or contract renegotiations.
What regulatory status does Isovue-300 have in the US and globally?
US regulatory position
- Isovue-300 is FDA-approved for imaging uses consistent with labeled iodinated contrast indications.
- Post-marketing safety monitoring applies to the class.
- Interchangeability between competing iodinated contrasts is common at the clinical level, subject to label and protocol alignment.
Global position
- Iodinated contrast agents including iopamidol are widely available in major markets.
- Market access outside the US typically depends on:
- Local labeling requirements.
- Sterile manufacturing compliance.
- Local tendering and hospital formularies.
Key litigation and settlement risks affecting Isovue-300 market access
Practical assessment
- For mature contrast products, litigation risk is not the primary determinant of market access; authorization and supply are.
- Where patent listings exist, settlements can:
- Allow earlier generic entry with label carveouts.
- Delay entry in limited claim sets.
Business impact to track
- Changes in FDA labeling due to settlement terms.
- Distributor contract behavior following generic entry waves.
Manufacturing and IP barriers: what prevents or slows new entrants for Isovue-300?
Manufacturing constraints
- Sterile injectable production requires robust aseptic processing.
- Consistency in iodinated content and physicochemical properties is critical.
- Temperature and handling procedures affect stability and usability.
IP barriers
- Late-cycle process or packaging patents can create narrow but meaningful constraints.
- Method-of-use claims, if any, can create label litigation exposure if the entrant can’t fully carve out.
Key Takeaways
- Isovue-300 is a mature iodinated contrast medium with limited “new pivotal trial” momentum; current clinical activity is mostly post-market safety, protocol optimization, and workflow-focused studies.
- Market growth is tied to CT utilization, while revenue is constrained by ongoing pricing pressure from multi-source competition and contracting cycles.
- Exclusivity/patent impact is typically not a major driver in this category; market access is shaped by Orange Book listings (if any relevant), labeling alignment, and supply reliability.
- Competitive risk is best managed by contract strategy, distribution readiness, and monitoring of any narrow manufacturing or method claims that could affect label or launch timing.
FAQs
1) Does Isovue-300 have ongoing clinical trials for contrast-associated kidney injury risk mitigation?
Clinical activity in iopamidol typically targets CA-AKI risk protocols and safety endpoints, usually through post-authorization studies rather than pivotal trials.
2) What imaging procedures most commonly use Isovue-300?
CT-enhanced imaging and angiography protocols where iodinated nonionic contrast is indicated per label.
3) Are iopamidol generics interchangeable with Isovue-300 for hospital formularies?
In practice, interchangeability is common within iodinated contrast categories, subject to label and institution protocol.
4) What is the main driver of revenue changes for Isovue-300 in the US?
Pricing from contract renegotiations and multi-source competition, with volume tied to CT procedure throughput.
5) How do patent listings typically affect generic launches for mature contrast agents?
They can delay launches for narrow process or method-of-use claims, but broad exclusivity typically has already lapsed for active ingredients like iopamidol.
References
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- US FDA. Isovue-300 (iopamidol injection) Prescribing Information. (Accessed 2026).
- ClinicalTrials.gov. Studies for iopamidol and iodinated contrast media safety and protocol optimization. (Accessed 2026).
- American College of Radiology (ACR). Manual on Contrast Media. (Latest edition accessed 2026).
